IARC disputes report that attributes most types of cancer to "bad luck"

Share this content:

the ONA take:

Widespread media coverage has been given to a scientific study that compares the number of lifetime stem cell divisions across a wide range of tissues with lifetime cancer risk.

The study suggests that random mutations—or bad luck—are “the major contributors to cancer overall, often more important than either hereditary or external environmental factors.” The study authors argue that focusing on early detection of the disease is more significant than preventive measures.

The World Health Organization’s specialized cancer agency, the International Agency for Research on Cancer (IARC), however, disputes these findings, pointing to a serious contradiction with an extensive body of evidence as well as limitations and biases within the analysis.

Five decades of international epidemiological research demonstrates how most cancers may be prevalent in one population but not in another and that these patterns change over time. For example, colorectal cancer was once rare in Japan, but incidence has increased 4-fold in the past 20 years, an observation consistent with changes in environment and lifestyle exposures. Furthermore, IARC points out that the study emphasizes rare cancers, which make up only a small percentage of cancer cases.

The association between cell divisions and the risk of mutation and, therefore, of developing cancer, is clear; however, most cancers are strongly related to environment and lifestyle. The IARC argues that most common cancers can be prevented as evidenced by the impact of reductions in smoking leading to fewer lung cancer cases or lower rates of hepatocellular carcinoma among people vaccinated against hepatitis B virus.

Although investing in prevention measures for those cancers whose risk factors are known should continue, the IARC stresses that cancer risk should not be ascribed to bad luck.

Continuing the search for the causes of cancer is particularly important, especially in areas of the world with limited resources for facing the growing burden of cancer.

Tamoxifen decreases risk of breast cancer by 30% for 20 years
A scientific study compares the number of lifetime stem cell divisions across a wide range of tissues with lifetime cancer risk.
The International Agency for Research on Cancer (IARC), the World Health Organization's specialized cancer agency, strongly disagrees with the conclusion of a scientific report on the causes of human cancer published in the journal Science on 2 January 2015 by Dr Cristian Tomasetti and Dr Bert Vogelstein.
READ FULL ARTICLE From Medical News Today
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs